Company news

Altimmune, Inc. news in 2023

Altimmune, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

November 29, 2023

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update

November 6, 2023

Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

October 30, 2023

Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

October 25, 2023

Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023

October 24, 2023

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes

September 25, 2023

Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

September 11, 2023

Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update

August 9, 2023

Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

August 2, 2023

Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)

July 31, 2023

Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023

June 15, 2023

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023

June 14, 2023

Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update

May 10, 2023

Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

May 3, 2023

Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B

April 10, 2023

Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

March 26, 2023

Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial

March 20, 2023

Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

February 27, 2023

Altimmune Appoints Raymond Jordt as Chief Business Officer

January 3, 2023

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

January 3, 2023

Calls in 2023

Decks in 2023